Abstract
高龄、糖尿病(DM)和慢性肾脏疾病(CKD)不仅会增加慢性冠状动脉综合征(CCS)患者缺血事件的风险,还会增加其接受抗血小板治疗期间的出血风险。此类特殊人群可能需要调整治疗方案,尤其是亚洲的特殊人群,往往表现出与西方人群不同的临床特征。关于亚洲人群CCS高风险的分类和急性冠状动脉综合征(ACS)后使用新一代强效P2Y12受体抑制剂(如替格瑞洛和普拉格雷)的国际指南已相继发表。本共识总结了在特殊人群中使用强效P2Y12受体抑制剂的相关证据,提出了在冠状动脉疾病(CAD)特殊人群中应用标准疗程双联抗血小板治疗(DAPT)、短期DAPT和单一抗血小板治疗的推荐意见。本共识的特殊人群包括从ACS过渡至CCS,老年,或患有CKD、DM、多血管CAD和治疗期间发生出血并发症等特征的患者。.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.